1. G.J. Mossinghoff , “Overview of the Hatch-Waxman Act and Its Impact on the Drug Development Process,”Food and Drug Law Journal54, no. 2 ( 1999 ): 187 –194.
2. The price of innovation: new estimates of drug development costs
3. J.M. Reichert and C. Paquette, “Therapeutic Recombinant Proteins: Trends in U.S. Approvals 1982 to 2002,”Current Opinion in Molecular Therapeutics5, no. 2 ( 2003 ): 139 –147.
4. H. Grabowski , “Patents and New Product Development in the Pharmaceutical and Biotechnology Industries,”Georgetown Public Policy Review8, no. 2 ( 2003 ): 7 –24.
5. Generic Competition in the US Pharmaceutical Industry